tbuckley/cabot-search huggingface dataset:
Annals Graphic Medicine - Dr. Mom: A Glossary of Electronic Medical Record Alerts
Authors: Grace E. Farris
Journal: Annals of Internal Medicine (2020)

Web Exclusives7 January 2020Annals Graphic Medicine - Dr. Mom: A Glossary of Electronic Medical Record AlertsFREEGrace E. Farris, MDGrace E. Farris, MDMount Sinai School of Medicine, New York, New York (G.E.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G19-0075 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Mount Sinai School of Medicine, New York, New York (G.E.F.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G18-0042.Author/Illustrator Information: Grace E. Farris, MD, is an assistant professor of medicine at Icahn School of Medicine at Mount Sinai and chief of hospital medicine at Mount Sinai West hospital in New York, New York. You can view her work at her Web site: www.farrisgrace.com.About Dr. Mom: In Dr. Mom, physician and cartoonist Grace Farris examines work–life balance while mothering and doctoring. Dr. Mom appears monthly in Annals Graphic Medicine at Annals.org. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 January 2020Volume 172, Issue 1Page: W26-W27KeywordsConflicts of interestDisclosureElectronic medical recordsHospital medicineHospitalists ePublished: 7 January 2020 Issue Published: 7 January 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Deep Learning to Distinguish Benign from Malignant Renal Lesions Based on Routine MR Imaging
Authors: Ianto Lin Xi, Yijun Zhao, Robin Wang, Marcello Chang, Subhanik Purkayastha, Ken Chang, Raymond Y. Huang, Alvin C. Silva, Martin Vallières, Peiman Habibollahi, Yong Fan, Beiji Zou, Terence P. Gade, Paul J. Zhang, Michael C. Soulen, Zishu Zhang, Harrison X. Bai, S. William Stavropoulos
Journal: Clinical Cancer Research (2020)

Abstract Purpose: With increasing incidence of renal mass, it is important to make a pretreatment differentiation between benign renal mass and malignant tumor. We aimed to develop a deep learning model that distinguishes benign renal tumors from renal cell carcinoma (RCC) by applying a residual convolutional neural network (ResNet) on routine MR imaging. Experimental Design: Preoperative MR images (T2-weighted and T1-postcontrast sequences) of 1,162 renal lesions definitely diagnosed on pathology or imaging in a multicenter cohort were divided into training, validation, and test sets (70:20:10 split). An ensemble model based on ResNet was built combining clinical variables and T1C and T2WI MR images using a bagging classifier to predict renal tumor pathology. Final model performance was compared with expert interpretation and the most optimized radiomics model. Results: Among the 1,162 renal lesions, 655 were malignant and 507 were benign. Compared with a baseline zero rule algorithm, the ensemble deep learning model had a statistically significant higher test accuracy (0.70 vs. 0.56, P = 0.004). Compared with all experts averaged, the ensemble deep learning model had higher test accuracy (0.70 vs. 0.60, P = 0.053), sensitivity (0.92 vs. 0.80, P = 0.017), and specificity (0.41 vs. 0.35, P = 0.450). Compared with the radiomics model, the ensemble deep learning model had higher test accuracy (0.70 vs. 0.62, P = 0.081), sensitivity (0.92 vs. 0.79, P = 0.012), and specificity (0.41 vs. 0.39, P = 0.770). Conclusions: Deep learning can noninvasively distinguish benign renal tumors from RCC using conventional MR imaging in a multi-institutional dataset with good accuracy, sensitivity, and specificity comparable with experts and radiomics.
Cancer statistics, 2020
Authors: Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal
Journal: CA A Cancer Journal for Clinicians (2020)

Abstract Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population‐based cancer occurrence. Incidence data (through 2016) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2017) were collected by the National Center for Health Statistics. In 2020, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States. The cancer death rate rose until 1991, then fell continuously through 2017, resulting in an overall decline of 29% that translates into an estimated 2.9 million fewer cancer deaths than would have occurred if peak rates had persisted. This progress is driven by long‐term declines in death rates for the 4 leading cancers (lung, colorectal, breast, prostate); however, over the past decade (2008‐2017), reductions slowed for female breast and colorectal cancers, and halted for prostate cancer. In contrast, declines accelerated for lung cancer, from 3% annually during 2008 through 2013 to 5% during 2013 through 2017 in men and from 2% to almost 4% in women, spurring the largest ever single‐year drop in overall cancer mortality of 2.2% from 2016 to 2017. Yet lung cancer still caused more deaths in 2017 than breast, prostate, colorectal, and brain cancers combined. Recent mortality declines were also dramatic for melanoma of the skin in the wake of US Food and Drug Administration approval of new therapies for metastatic disease, escalating to 7% annually during 2013 through 2017 from 1% during 2006 through 2010 in men and women aged 50 to 64 years and from 2% to 3% in those aged 20 to 49 years; annual declines of 5% to 6% in individuals aged 65 years and older are particularly striking because rates in this age group were increasing prior to 2013. It is also notable that long‐term rapid increases in liver cancer mortality have attenuated in women and stabilized in men. In summary, slowing momentum for some cancers amenable to early detection is juxtaposed with notable gains for other common cancers.
L6.5 Personalized Medicine: An Update on 1,985 Patients with Advanced Cancer at Md Anderson Cancer Center
Authors: A.M. Tsimberidou, D.S. Hong, J.J. Wheler, Y. Ye, S. Fu, S.A. Piha-Paul, A. Naing, G.S. Falchook, F. Janku, R. Luthra, S. Wen, R. Kurzrock
Journal: Annals of Oncology (2012)
The Estimation of Life-Time for the Patients who Acquired Resistance to Standard Chemotherapies
Authors: T. Taniyama, K. Hashimoto, A. Hirakawa, N. Katsumata, M. Kodaira, K. Yonemori, M. Yunokawa, C. Shimizu, K. Tamura, M. Ando, Y. Fujiwara
Journal: Annals of Oncology (2012)
Metformin in Chemotherapy-Naïve Castration Resistant Prostate Cancer (CRPC): A Multicenter Phase II Trial (SAKK 08/09)
Authors: C.A. Rothermundt, R. Cathomas, A. Templeton, R.C. Winterhalder, R. Strebel, D. Baertschi, M. Pollak, L. Lui, S. Crowe, S. Gillessen
Journal: Annals of Oncology (2012)
Cancer Vaccination Trial with Novel Multiple Peptides in Previously Treated Advanced Non-Small-Cell Lung Cancer
Authors: T. Hirose, H. Noda, K. Okuda, S. Abe, Y. Oto, S. Kusumoto, T. Sugiyama, H. Ishida, T. Shirai, M. Nakashima, T. Yamaoka, T. Ohmori, K. Yoshida, Y. Nakamura, M. Adachi
Journal: Annals of Oncology (2012)
Overexpression of FOXQ1 is Important Factor in Tumorigenecity and Tumor Growth
Authors: H. Kaneda, T. Arao, K. Tanaka, K. Matsumoto, H. Kimura, T. Nagai, K. Sakai, Y. Fujita, M.A. De Velasco, Y. Yamada, J. Tsurutani, I. Okamoto, K. Nakagawa, K. Nishio
Journal: Annals of Oncology (2012)
Corrections to “Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines”
Authors: M. Aapro, Y. Beguin, C. Bokemeyer, M. Dicato, P. Gascón, J. Glaspy, A. Hofmann, H. Link, T. Littlewood, H. Ludwig, A. Österborg, P. Pronzato, V. Santini, D. Schrijvers, R. Stauder, K. Jordan, J. Herrstedt
Journal: Annals of Oncology (2018)
Neurons, Receptors, and Channels
Authors: David A. Brown
Journal: The Annual Review of Pharmacology and Toxicology (2020)

Here, I recount some adventures that I and my colleagues have had over some 60 years since 1957 studying the effects of drugs and neurotransmitters on neuronal excitability and ion channel function, largely, but not exclusively, using sympathetic neurons as test objects. Studies include effects of centrally active drugs on sympathetic transmission; neuronal action and neuroglial uptake of GABA in the ganglia and brain; the action of muscarinic agonists on sympathetic neurons; the action of bradykinin on neuroblastoma-derived cells; and the identification of M-current as a target for muscarinic action, including experiments to determine its distribution, molecular composition, neurotransmitter sensitivity, and intracellular regulation by phospholipids and their hydrolysis products. Techniques used include electrophysiological recording (extracellular, intracellular microelectrode, whole-cell, and single-channel patch-clamp), autoradiography, messenger RNA and complementary DNA expression, antibody injection, antisense knockdown, and membrane-targeted lipidated peptides. I finish with some recollections about my scientific career, funding, and changes in laboratory life and pharmacology research over the past 60 years.
Keeping guidelines current: A six-month evaluation of Wiki-based lung cancer guidelines.
Authors: Ian N. Olver, Jutta von Dincklage, Andrew Garrett, Laura Holliday, Christine Vuletich
Journal: Journal of Clinical Oncology (2013)

e17587 Background: The challenge for clinical practice guidelines is keeping them regularly updated with new evidence, and widely disseminated in a cost effective manner. This is difficult with printed guidelines and so Cancer Council Australia developed an internet based wiki platform for guidelines and assessed the impact of wiki lung cancer treatment guidelines 6 months after their development. Methods: The key steps in guideline development of identifying questions, literature searching, appraisal of papers, experts writing evidence-based recommendations and wide public consultation and dissemination were integrated in an access-protected wiki. Google web analytics was used to monitor usage. New papers are added and the writers continuously engaged in updating their questions. The evaluation spanned 6 months from May to November 2012. Results: The lung cancer guidelines had 67 clinical questions and 2076 articles were critically appraised. In the first month during public consultation there were 1055 visits to the site and 2955 visits in the following 5 months. The guidelines were accessed from a mobile device by 7% for consultation and 11% subsequently. During the consultation 80% of visits were from Australia, 6% New Zealand, 4% USA and 2% UK. In the consultation period 56% visits resulted from organic search traffic, 31% direct access and 13% referrals and subsequently 72% from searches, 19% direct and 11% referrals. The guideline partner Cancer Australia was the major source of referral (26% during consultation and 25% subsequently) as well as Cancer Council’s main website 9% during the consultation and 38% subsequently. Facebook was responsible for 6-8% of referrals highlighting the role of social media in promoting guidelines. The average highest visit duration by a country was 9.06 minutes in the consultation month (Australia) and 7.24 for Canada. Bounce rates vary widely from 20% (Germany) to above 70% (USA, UK, India). Conclusions: Both clinicians and the public will engage with wiki guidelines and they reach a wide international audience.
Overuse of short-acting β<sub>2</sub>-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme
Authors: Bright I. Nwaru, Magnus Ekström, Pål Hasvold, Fredrik Wiklund, Gunilla Telg, Christer Janson
Journal: European Respiratory Journal (2020)

Overuse of short-acting β2-agonists (SABA) may indicate poor asthma control and adverse health outcomes. Contemporary population-based data on use, risk factors and impact of SABA (over)use on asthma exacerbations and mortality are scarce, prompting initiation of the global SABINA (SABA use IN Asthma) programme.By linking data from Swedish national registries, asthma patients aged 12-45 years with two or more collections of drugs for obstructive lung disease during 2006-2014 were included. SABA overuse was defined as collection of more than two SABA canisters in a 1-year baseline period following inclusion. SABA use was grouped into 3-5, 6-10 and ≥11 canisters per baseline-year. Cox regression was used to examine associations between SABA use and exacerbation (hospitalisations and/or oral corticosteroid claims) and mortality.The analysis included 365 324 asthma patients (mean age 27.6 years; 55% female); average follow-up was 85.4 months. 30% overused SABA, with 21% collecting 3-5 canisters per year, 7% collecting 6-10 canisters per year and 2% collecting ≥11 canisters per year. Increasing number of collected SABA canisters was associated with increased risk of exacerbation, as follows. 3-5 canisters: hazard ratio (HR) 1.26 (95% CI 1.24-1.28); 6-10 canisters: 1.44 (1.41-1.46); and ≥11 canisters: 1.77 (1.72-1.83), compared to two or fewer canisters per year. Higher SABA use was associated with incrementally increased mortality risk (2564 deaths observed), as follows. 3-5 canisters: HR 1.26 (95% CI 1.14-1.39); 6-10 canisters 1.67 (1.49-1.87); and ≥11 canisters: 2.35 (2.02-2.72) compared to two or fewer canisters per year.One-third of asthma patients in Sweden collected three or more SABA canisters annually. SABA overuse was associated with increased risks of exacerbation and mortality. These findings emphasise that monitoring of SABA usage should be key in improving asthma management.
経食道及び/あるいは心腔内エコー法のガイドによるブロッケンブロウ経心房中隔穿刺と左心房カニューレ挿入 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Kyo S, Miyamoto N, Matsumura M, Motoyama T, Omoto R
Journal: Circulation (1994)
Updated Overall Survival Analysis in Oceans, a Randomized Phase 3 Trial of Gemcitabine (G) + Carboplatin (C) and Bevacizumab (BV) or Placebo (PL) Followed by BV or PL in Platinum-Sensitive Recurrent Epithelial Ovarian (ROC), Primary Peritoneal (PPC), or Fallopian Tube Cancer (FTC)
Authors: C. Aghajanian, L.R. Nycum, B. Goff, H. Nguyen, A. Husain, S.V. Blank
Journal: Annals of Oncology (2012)
Lurbinectedin (PM01183) in Combination with Gemcitabine (GEM). Preliminary Results of an Ongoing Phase IB Study
Authors: E. Calvo, L. Ares, M. Foster, I. López Calderero, A. Cubillo, A. Velasco, V. Boni, D. Wilkins, A. Soto-Matos, S. Szyldergemajn
Journal: Annals of Oncology (2012)
Final Analysis of Randomized Phase III Study WJOG4007 Comparing Irinotecan (CPT-11) with weekly Paclitaxel (WPTX) in advanced Gastric Cancer (AGC) Refractory to Chemotherapy (CT) of Fluoropyrimidine Plus Platinum (FP)
Authors: T. Nishina, S. Hironaka, A. Tsuji, K. Suzuki, T. Otsuji, T. Shibata, S. Morita, I. Okamoto, N. Boku, I. Hyodo
Journal: Annals of Oncology (2012)
Prognostic Value of BRAF and KRAS Mutations in Colorectal Cancer Patients
Authors: E.P. Murata, A. Stradella, D. Páez, M. Tobeña Puyal, A. Sebio Garcia, A. Gonzalez, E. Targarona, M. Baiget, A. Barnadas, M. Martín-Richard
Journal: Annals of Oncology (2012)
Breast cancer stem cells: A novel therapy for breast cancer.
Authors: Soma Mukhopadhyay, Sudeshna Gangopadhyay, Swati Dasgupta, Saubhik Sengupta, Ujjal Kanti Ray, Pooja Hor, Ashis Mukhopadhyay
Journal: Journal of Clinical Oncology (2012)

e13030 Background: Simple BRCA screening is insufficient for ‘event-free survival’ as breast cancer is clinically and pathologically an extremely heterogeneous disease. Targeting Breast Cancer Stem Cells (BCSCs) present in bone marrow and breast tissues is a lucrative alternative. Identification of BCSCs is salient aspect of our research. Invasive and mesenchymal property of BCSCs with CD44+/CD24 low /ALDH1+ phenotype has made them a promising target for eliminating metastatic capacity of primary tumors. We hypothesize that ability to therapeutically attack stem cell hinges upon identifying unique targets like cell surface markers and this will decide development of specific target therapies. Methods: A total of 10 early chemo-naive patients with biopsy proven triple-negative metastatic breast cancer in the age group of 18-36 yr.s (mean age 28 yr.s) were selected randomly and tested for CD44/CD24 cell surface markers following immunosorting using magnetic cell sorter and immunophenotyping by flowcytometric analysis. Isolated BCSCs were cultured for in vitro drug sensitivity towards platinum, anthracycline and docetaxel. Correlation was drawn between cell differentiation, % of stem cells and drug response. Accordingly chemotherapy was designed for a particular patient. % of BCSCs in pre- and post-chemotherapeutic condition was further compared. Results: We have detected BCSCs in 90% of cases. Among positive samples, 89% patients showed platinum sensitivity and rest were found to be anthracycline sensitive. No sensitivity to docetaxel was observed. In lieu of this, cisplatin was applied in vivo and % of BCSCs came down to 6.58% from initial 11.16% (for a representative case). Conclusions: Thus primary aim to target BCSCs at the onset of tumors in breast cancer patients to control metastasis and relapse of disease was somewhat obtained. We further plan to correlate ratio of selected markers present in patients in pre- and post-chemotherapeutic condition with time to recurrence, mortality, morbidity and progression-free survival. Finally, if no BCSCs prevail after chemotherapy, then patients would be kept under observation and if traces are found, we would proceed to targeted therapy trial like PARP inhibitor or autologous stem cell replacement.
Rude behaviour towards SAS doctors is unacceptable, says GMC
Authors: Gareth Iacobucci
Journal: BMJ (2020)

About one in four doctors in specialty and associate specialist (SAS) and “locally employed” (LE) roles experience rudeness, incivility, belittling, and humiliation in the workplace, a survey by the General Medical Council indicates.1

Over 6400 doctors took part in the GMC’s first ever survey of SAS and LE doctors (a response rate of 13.5%), split almost equally between SAS doctors (3151) and doctors working in an LE post (3316) and representing around a quarter of the UK’s SAS doctors and 10% of LE doctors. LE doctors can have a range of contracts and job titles, often for a fixed term. Many have recently completed their foundation training and will return to …
Health Care Administrative Costs in the United States and Canada, 2017
Authors: David U. Himmelstein, Terry Campbell, Steffie Woolhandler
Journal: Annals of Internal Medicine (2020)

Before Canada's single-payer reform, its payment system, health costs, and number of health administrative personnel per capita resembled those of the United States. By 1999, administration accounted for 31% of U.S. health expenditures versus 16.7% in Canada. No recent comprehensive analyses of those costs are available.To quantify 2017 spending for administration by insurers and providers.Analyses of government reports, accounting data that providers file with regulators, surveys of physicians, and census-collected data on employment in health care.United States and Canada.Insurance overhead; administrative expenditures of hospitals, physicians, nursing homes, home care agencies, and hospices.U.S. insurers and providers spent $812 billion on administration, amounting to $2497 per capita (34.2% of national health expenditures) versus $551 per capita (17.0%) in Canada: $844 versus $146 on insurers' overhead; $933 versus $196 for hospital administration; $255 versus $123 for nursing home, home care, and hospice administration; and $465 versus $87 for physicians' insurance-related costs. Of the 3.2-percentage point increase in administration's share of U.S. health expenditures since 1999, 2.4 percentage points was due to growth in private insurers' overhead, mostly because of high overhead in their Medicare and Medicaid managed-care plans.Estimates exclude dentists, pharmacies, and some other providers; accounting categories for the 2 countries differ somewhat; and methodological changes probably resulted in an underestimate of administrative cost growth since 1999.The gap in health administrative spending between the United States and Canada is large and widening, and it apparently reflects the inefficiencies of the U.S. private insurance-based, multipayer system. The prices that U.S. medical providers charge incorporate a hidden surcharge to cover their costly administrative burden.None.
The cost of insecurity: from flare-up to control of a major Ebola virus disease hotspot during the outbreak in the Democratic Republic of the Congo, 2019
Authors: Thibaut Jombart, Christopher I Jarvis, Samuel Mesfin, Nabil Tabal, Mathias Mossoko, Luigino Minikulu Mpia, Aaron Aruna Abedi, Sonia Chene, Ekokobe Elias Forbin, Marie Roseline D Belizaire, Xavier de Radiguès, Richy Ngombo, Yannick Tutu, Flavio Finger, Madeleine Crowe, W John Edmunds, Justus Nsio, Abdoulaye Yam, Boubacar Diallo, Abdou Salam Gueye, Steve Ahuka-Mundeke, Michel Yao, Ibrahima Socé Fall
Journal: Eurosurveillance (2020)

The ongoing Ebola outbreak in the eastern Democratic Republic of the Congo is facing unprecedented levels of insecurity and violence. We evaluate the likely impact in terms of added transmissibility and cases of major security incidents in the Butembo coordination hub. We also show that despite this additional burden, an adapted response strategy involving enlarged ring vaccination around clusters of cases and enhanced community engagement managed to bring this main hotspot under control.
Surgical Resection of Locally Advanced Primary Tumor in Patients with Distant Metastatic Breast Cancer at Diagnosis: Results of A Retrospective Comparative Study
Authors: S. Arifi, F.Z. Hijri, Z. Benbrahim, Y. Akasbi, S. Elfakir, N. Mellas, A. Melhouf, A. Banani, O. El Mesbahi
Journal: Annals of Oncology (2012)
A Phase II Trial of Salvage Treatment with Gemcitabine and S-1 Combination in Heavily Pretreated Patients with Metastatic Colorectal Cancer
Authors: S.J. Sym, J. Hong, M. Jung, J. Park, E.K. Cho, J.H. Lee, W.-S. Lee, J.-H. Baek, D.B. Shin
Journal: Annals of Oncology (2012)